MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation
about
RASopathies: unraveling mechanisms with animal modelsThe molecular basis of cognitive deficits in pervasive developmental disordersPaternal age effect mutations and selfish spermatogonial selection: causes and consequences for human diseaseStructural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)RAF1 mutations in childhood-onset dilated cardiomyopathyNext-generation sequencing identifies rare variants associated with Noonan syndromeA cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling.Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafishRas in cancer and developmental diseasesGLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesityK-RasV14I recapitulates Noonan syndrome in mice.Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.BRAF gene: From human cancers to developmental syndromes.Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?Cardiomyopathies in Noonan syndrome and the other RASopathies.Toward Personalized Medicine: Does Genetic Diagnosis of Pediatric Cardiomyopathy Influence Patient Management?In vivo natriuretic peptide reporter assay identifies chemical modifiers of hypertrophic cardiomyopathy signalling.MEK Inhibitors Reverse cAMP-Mediated Anxiety in ZebrafishIncreased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutantsAnchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy.The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc42The role of the paracrine/autocrine mediator endothelin-1 in regulation of cardiac contractility and growth.Endothelial ERK signaling controls lymphatic fate specificationRSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome.Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy.Raf-mediated cardiac hypertrophy in adult DrosophilaFoxc1 and Foxc2 deletion causes abnormal lymphangiogenesis and correlates with ERK hyperactivationConstitutively active MEK1 rescues cardiac dysfunction caused by overexpressed GSK-3α during aging and hemodynamic pressure overload.Autonomous and Non-autonomous Defects Underlie Hypertrophic Cardiomyopathy in BRAF-Mutant hiPSC-Derived Cardiomyocytes.Cardiac hypertrophy induced by active Raf depends on Yorkie-mediated transcription.Low-dose dasatinib rescues cardiac function in Noonan syndrome.Systematic morphological profiling of human gene and allele function via Cell Painting.The musculoskeletal phenotype of the RASopathies.Signaling to cardiac hypertrophy: insights from human and mouse RASopathies.Ras/MAPK syndromes and childhood hemato-oncological diseases.Key role of ERK1/2 molecular scaffolds in heart pathology.Heart failure in congenital heart disease: the role of genes and hemodynamics.Recent advances in RASopathies.
P2860
Q26800379-CB46ED44-0D02-42E3-9214-5C5C9035A955Q26991872-B6F5D46C-03D1-4AFB-89DE-C5C1AACB9F44Q28259472-9A39B9E2-FB6D-4E04-8918-195732450C24Q33556868-82401BD2-7070-4D50-8CA4-3DE10C5ED81CQ33726801-7FF2DA0D-4EAA-4BFA-9840-429486909787Q34025431-319E39ED-BE6E-4FCE-AB25-C7460FFE6090Q34035845-C6CA588B-0F40-4B5C-8A2E-37992DC28124Q34149419-E4F8EEA8-2350-49F5-93C6-A156FBFCEF2EQ34202697-90A99090-AD77-4BAE-9EF1-F135CC79A0A3Q34336097-66D52797-106D-4DE8-BBF7-A6CED94D5604Q34409247-831EDD65-1E78-4234-9D89-4008B366C8F0Q34581270-CCB22430-104B-48B8-B420-92C789B2ACB3Q34627120-440262AC-2B51-41B0-ACC9-A8CE67ED7A5BQ35802430-E728F5C5-43C5-4850-860C-24081B82B76BQ35837138-1D977786-4110-4E3D-B785-90F1F735294CQ36025665-CFD9977F-AE08-49C3-8527-827B3340891FQ36057294-31B95FCB-AA7E-47FF-A26B-F81816B38BD4Q36057314-2A27A22C-A303-4A20-A042-1A4F3792542DQ36135276-5411079B-72D4-41CF-AC04-32CF1689F10EQ36215799-5959ED39-C448-475F-BD2D-CFE79764DE2AQ36277286-1BBA3303-8784-478E-A9C1-FE789799259AQ36510904-A9E50450-C709-4691-8999-76501E04D704Q36528106-B64FD525-E6C3-499E-ACA0-6145DAE23AEFQ36610320-66BCEC32-EF8F-4B70-A850-FE490361E18CQ36638093-9268AFAE-949C-45D2-9A63-E19EB2E80F1DQ36839960-0B67E547-6956-46CC-BAF5-1DCBC585B8BEQ36932490-1605B340-1FF7-4AB7-9AFC-49708646D3EDQ36981830-D710AB87-F390-4436-95AF-F9C51037F2C6Q37042262-2BF1FE00-19E0-4EF5-959C-D99CA0A038E5Q37174611-E77213FC-1022-4A5F-A0ED-485BDDF63D9AQ37274416-C6B36A6C-2EE2-4313-866D-7CF6E9B9DFBBQ37460894-E91280FC-C85E-4911-8D9C-048CE6F72BBEQ37469169-EDD5D69E-E356-4488-A4E2-E8B6088B97BEQ37745645-DF95681B-8DD9-458F-B2EA-196F72AA8C13Q37865455-D9D1BFE0-6D8B-477C-831F-D758A2B3D8F7Q38009216-5E507E2D-EA45-4D24-B50A-6B4E4B531191Q38068387-26B92CE3-C3B7-4122-A7AA-BCA37F433235Q38093445-15048406-578B-46C1-8877-6058CAA3FA09Q38184398-2C9124C8-3D2F-4CA7-8E28-BD6ADE98E859Q38601758-21662C28-6422-4438-812F-17858136D30D
P2860
MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
MEK-ERK pathway modulation ame ...... drome associated with the Raf1
@nl
MEK-ERK pathway modulation ame ...... with the Raf1(L613V) mutation
@ast
MEK-ERK pathway modulation ame ...... with the Raf1(L613V) mutation
@en
type
label
MEK-ERK pathway modulation ame ...... drome associated with the Raf1
@nl
MEK-ERK pathway modulation ame ...... with the Raf1(L613V) mutation
@ast
MEK-ERK pathway modulation ame ...... with the Raf1(L613V) mutation
@en
prefLabel
MEK-ERK pathway modulation ame ...... drome associated with the Raf1
@nl
MEK-ERK pathway modulation ame ...... with the Raf1(L613V) mutation
@ast
MEK-ERK pathway modulation ame ...... with the Raf1(L613V) mutation
@en
P2093
P2860
P356
P1476
MEK-ERK pathway modulation ame ...... with the Raf1(L613V) mutation
@en
P2093
Benjamin G Neel
Jenny H Hong
Jeremy Simpson
Kyoung-Han Kim
Nirusha K Thavarajah
Peter H Backx
Toshiyuki Araki
P2860
P304
P356
10.1172/JCI44929
P407
P577
2011-02-21T00:00:00Z